Immune recovery and the risk of CMV/ EBV reactivation in children post allogeneic haematopoietic stem cell transplantation.
Immune reconstitution was studied prospectively in 86 children who underwent allogeneic haematopoietic stem cell transplantation (HSCT). We analysed the risk of cytomegalovirus (CMV) and Epstein-Barr virus (EBV) reactivation in correlation with the kinetics of immune recovery and in relation to other potential risk factors that may influence the reactivation of these viruses including: diagnosis, type of HSCT, source of stem cells, type of conditioning, or the occurrence of graft-versus-host disease (GvHD). The absolute number of lymphocyte subpopulations in peripheral blood was evaluated in seven timepoints following HSCT. Significantly lower values of both CD3+and CD3+CD8+lymphocytes on day +14 and significantly higher values of both these subsets on day +168 post-transplant in patients with CMV reactivation were observed. Significantly lower values of CD3+CD4+subpopulation were noted in patients with CMV reactivation on day +28 post allo-HSCT. Significantly lower lymphocyte values in the group with EBV reactivation comparing with the group without EBV reactivation were confirmed only in the case of pan-B lymphocytes (CD19+) subpopulation on day +21, +28, and +84 post allo-HSCT. We identified the impact of CMV reactivation on occurrence of the intestinal acute GvHD, which occurred more frequently in the group with CMV reactivation compared with patients without reactivation. Higher incidence of chronic GvHD was also observed in patients with CMV reactivation compared to the group without reactivation. EBV reactivation occurred more frequently in patients receiving transplants from matched unrelated donors, in particular after peripheral blood stem cell transplantation and while implementing antithymocyte globulin as GvHD prophylaxis.
Department of Paediatric Haematology, Oncology, and Bone Marrow Transplantation, Wroclaw Medical University, Poland.
Małgorzata
M
Janeczko
Department of Paediatric Haematology, Oncology, and Bone Marrow Transplantation, Wroclaw Medical University, Poland.
Monika
M
Mielcarek
Department of Paediatric Haematology, Oncology, and Bone Marrow Transplantation, Wroclaw Medical University, Poland.
Blanka
B
Rybka
Department of Paediatric Haematology, Oncology, and Bone Marrow Transplantation, Wroclaw Medical University, Poland.
Renata
R
Ryczan-Krawczyk
Department of Paediatric Haematology, Oncology, and Bone Marrow Transplantation, Wroclaw Medical University, Poland.
Dorota
D
Noworolska-Sauren
Department of Paediatric Haematology, Oncology, and Bone Marrow Transplantation, Wroclaw Medical University, Poland.
Krzysztof
K
Kałwak
CMV reactivation; EBV reactivation; GvHD; allogeneic HSCT; children; immune recovery